TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Mucosal Resection and Cellular Matrix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Able to provide consent~* Scheduled for standard of care endoscopy that may require initial EMR evaluation of esophageal lesions~* Histological evidence of intestinal metaplasia with dysplasia or intramucosal carcinoma~Exclusion Criteria~* Pregnant women~* Prior esophageal EMR or ESD in the same region~* Anyone unable to provide informed consent~* Medical co-morbidities precluding EGD evaluation~* History of chemoradiotherapy to the neck/esophagus~* Unable to stop anticoagulation therapy (non-steroid anti-inflammatory medications are permissible)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Endoscopic submucosal resection with Extracelluar Matrix (Type: ACTIVE_COMPARATOR): Subjects with lesions that lift and are amenable to cap-assisted endoscopic submucosal resection (EMR) will receive extracellular matrix (ECM) to the defect site.
- Endoscopic submucosal resection standard of care (Type: NO_INTERVENTION): Subjects with lesions that lift and are amenable to cap-assisted endoscopic submucosal resection (EMR) will receive standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with cholesterol levels not controlled on ongoing stable statin treatment~Exclusion Criteria:~* LDL-C levels \> 250 mg/dL (6.48 mmol/L)~* Triglycerides \>350 mg/dL (3.95 mmol/L)~* Conditions / situations such as:~  * presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels~ * Active liver disease~ * Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease~ * Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive~* Pregnant or breast-feeding women,~* Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 25 mg/day AVE5530 (Type: EXPERIMENTAL): None
- 50 mg/day AVE5530 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ability to provide written informed consent and comply with study assessment for the full duration of the study.~2. age ≥ 21~3. diagnosis of glaucoma and determined to be candidate for therapy with tube insertion.~Exclusion Criteria:~1. pregnant or lactating females~2. Persons on oral contraceptives and women of child-bearing age~3. prior enrollment in the study~4. any conditions the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~5. participation in another simultaneous medical investigation or trial~6. history of active inflammatory, infectious, or idiopathic keratitis precluding view of anterior segment structures~7. previous injections of ranibizumab in either eye.~8. Persons on Plavix (clopidogrel bisulfate) and coumadin~9. Persons with uncontrolled high blood pressure~10. Persons with renal or liver disease

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: ACTIVE_COMPARATOR): Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
- Usual care (Type: NO_INTERVENTION): Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The study population tested will be recruited from ambulatory outpatients (presenting at the emergency unit or outpatient clinic) suspected of having DVT.~* Patient is \< 80 years old.~* Patient presenting at least one of these symptoms indicative of proximal DVT: leg pain, tenderness (discomfort through palpation), leg swelling and /or edema,~* Patient has confirmed proximal DVT by imaging~* Low or moderate Wells score~* Patient provides written informed consent to participate in the sample collection~Exclusion Criteria:~* Patient presenting with a condition that may be associated with increased D-dimer levels, even in the absence of VTE, such as:~  1. Fibrinolytic therapy within the previous seven (7) days,~ 2. Bone fracture or surgery (with general anesthesia longer than thirty (30) minutes) within the previous one (1) month,~ 3. Deep hematoma diagnosed by imaging techniques within the previous one (1) month,~ 4. Disseminated malignancies and active cancer (active cancer defined as: cancer for which therapeutic or palliative treatment is either ongoing at the time of enrolment or has stopped less than six (6) months before enrolment),~ 5. Sepsis, severe infections, pneumonia within the previous 1 month,~ 6. Known liver cirrhosis,~ 7. Pregnancy or post-partum within the previous 1 month,~ 8. Atherosclerotic vascular disease thrombosis within the previous 1month (e.g. myocardial infarction, stroke, coronary syndrome, peripheral artery disease stage III or IV),~ 9. Sickle cell disease,~* Patients presenting with a suspect thrombotic event related to catheter implantation~* Ongoing therapeutic anticoagulants (curative and preventive treatment) starting twenty four (24) hours or more before the blood drawing for D-dimer testing

- Gender: ALL
- Minimum Age: None
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Deep Venous Thrombosis (DVT) (Type: None): DVT diagnosed by imaging technique with a low or moderate Wells score

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Improving End of Life Care in Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: FAMILY_BASED
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Head and neck cancer patients who received their treatment at MSKCC who have died of noncutaneous squamous cell carcinomas of the upper aerodigestive tract and for whom family / next of kin contact information is available.~* Time of patient death must have been at least 6 months ago and no more than 4 years ago~* Patient age at time of death must be over 21 years of age.~* Those interviewed must be English-fluent.~Exclusion Criteria:~* Non-English speaking interviewees~* Next-of-kin who reported being unfamiliar with care received during the last month of life~* Next-of-kin who did not identify themselves as one of the patient's primary social supports during the last month of life~* Next-of-kin who were not physically present with the deceased at least once during the last week of his/her life~* Next-of-kin under age 21

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- families or next-of-kin of deceased patients (Type: None): The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be eligible for the study: (All answers must be YES for subject to be eligible.)~1. Subject must have a suspected SCLC or NSCLC.~2. Subject must be 18-90 years of age.~3. Subject must have been referred for a clinically indicated PET-CT.~4. Subject must provide written informed consent prior to any study-related procedures being performed.~5. Subject must be willing to comply with all clinical study procedures.~Exclusion Criteria:~The presence of the following excludes subjects from the study: (All answers must be NO for subject to be eligible.)~1. Subject is a pregnant or nursing female. Exclude the possibility of pregnancy:~   * By testing (serum or urine βHCG) within 24 hours before contrast agent administration, or~  * By surgical sterilization, or~  * Post-menopausal, with minimum one (1) year history without menses.~2. Subject has impaired renal function (eGFR\<30 mL/min).~3. Subject has an acute psychiatric disorder or is cognitively impaired.~4. Subject is using or is dependent on substances of abuse.~5. Subject is unwilling to comply with the requirements of the protocol.~6. Subject has an allergy against iodinated contrast agents and cannot be premedicated.~7. Subject is in acute unstable condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acute Balloon Angioplasty vs. Traditional Early Invasive Treatment of Non-ST-Elevation Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with symptoms and signs of NSTEMI and significant ECG changes (Either ≥4mm cumulated ST-segment depression (horizontal or descending), or ≥2mm ST-segment depression (horizontal or descending) in two associated leads)and/or patients with positive biomarkers for myocardial infarction (troponin T) measured in the ambulance (prehospital measurement of biomarkers).~2. Age above 18 years.~3. Tentative diagnosis made pre-hospitally.~Exclusion Criteria:~1. Severe mental or psychiatric disease (eg. psychosis, dementia, bipolar disorder or depression) as well as other conditions making it impossible to obtain informed consent.~2. Prior CABG (Coronary artery bypass graft) operation.~3. Patients with ST-depression presumed to be caused by tachycardia or cardiac hypertrophy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Primary PCI in patients with acute Non-STEMI
- 2 (Type: ACTIVE_COMPARATOR): Standard medical treatment and coronary angiography after 3 days in patients with Non-STEMI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed cases of SARS-CoV-2 infection hospitalized in reference services identified by the Ministry of Health and Social Action of Senegal~* Adults (≥18 years)~* Full understanding and consent to participate to the trial~* No contraindications to taking the tested treatments~* Clinical status from 3 to 5 on the seven-category ordinal scale~* Pneumonia highlighted by infiltration of the lungs by chest CT scan or chest radiography~* Absence of contraindications to radiographic examinations (X-ray and/or CT scan) for diagnosis and/or follow-up~* Inclusion in the 72 hours following the radiological pneumonia confirmation~Non-inclusion Criteria:~* Pregnant or breastfeeding woman~* Patient at high risk of death within 3 days of inclusion, in the clinician's opinion~* Corrected QT interval (QTc) \>500ms~* Heart electrical dysfunction: atrioventricular block Mobitz type II second-degree, high-grade or complete without a functioning pacemaker~* Uncontrolled and clinically significant heart diseases, such as arrhythmia, angina or decompensated congestive heart failure~* Kidney failure (Cl \< 30 mL/min)~* Patients with liver cirrhosis whose Child-Puch score is B or C~* Patients who have liver disease abnormalities with ALT or AST \> 5 times ULN~* Patients who have a known HIV status~* Patients who have other clinically-important diseases in decompensation which may interfere with the evaluation or completion of the tested treatment's procedure, in the clinician's opinion~* Patients with a clinical or psychological condition which, in the clinician's opinion, does not allow adequate evaluation of the tested treatment~* Known allergy to the studied treatment regimen~* Other contraindications with the studied treatment regimen~* Known drug-drug interaction with a treatment usually taken by the participant contraindicating one of the studied treatment regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: NO_INTERVENTION): The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.
- Standard of Care + Nafamostat mesilate (Type: EXPERIMENTAL): * The Standard of Care is the treatment which is the most adapted to the patient in the clinician's opinion. It could include the combination of Hydroxychloroquine and Azithromycin in the absence of contraindication.~* Nafamostat mesilate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~FOR SCREENING~* Patients must have a histopathologic diagnosis of GBM.~* Patients from 5 to 65 years of age with GBM.~FOR TREATMENT~* GBM has progressed following primary therapy.~* Tumor is CMV pp65 or IE1 positive by immunohistochemistry (IHC).~* Subjects must have pulse oximetry \> or = 94 % on no supplemental oxygen.~* Creatinine clearance must be \> 50 cc/min as estimated by patient's serum creatinine, weight, and age.~* Bilirubin must be \< 2.0 mg/dl and SGOT/SGPT \< 2.5 X normal.~* ECOG performance status must be \< or = 2, and for patients \<16 years of age, Lansky performance status must be \> or = 70%.~Exclusion Criteria:~* Pregnant females~* Subjects who are moribund or who because of cardiac, pulmonary, renal, hepatic or neurologic dysfunction are not expected to survive one month following the T cell infusion

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- GBM Treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All the criteria below have to be completed:~1. Systemic lupus erythematosus (SLE) according to the American College of Rheumatology (ACR) classification criteria and/or SLICC: according to the thematic protocol (Petri M, et al., Arthritis Rheum, 2012);~2. Age ≥18 years;~3. Lupus Glomerulonephritis Class III, IV or V according to the International Society of Nephrology (ISN)/Renal Pathology Society (RPS) Classification confirmed on renal biopsy (according to the routine protocol of our outpatient clinic) performed up to 3 months to 1 year prior to selection;~4. Menopause or use contraception method;~5. Informed consent.~Exclusion Criteria:~1. Creatinine clearance \< 40 ml/min calculated (Cockcroft \& Gault);~2. Intolerance to medication;~3. Absolute neutrophil count \< 1,000/mm3;~4. Pregnancy or breastfeeding;~5. Infection requiring hospitalization;~6. Patients who used Cyclophosphamide in the last 6 months or biological in the last year;~7. Thrombotic renal microangiopathy;~8. Chronic terminal renal disease and/or class VI biopsy;~9. Non-adhesion profile;~10. Need to use another therapeutic scheme;~11. GC dose in the last 3 months not greater than 20mg/day.~11.Central nervous system (CNS) disorders or hemolytic anemia and severe thrombocytopenia (\< 50,000 platelets/mm3).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eurolupus: Cyclophosphamide + Methylprednisolone + oral GC (Type: ACTIVE_COMPARATOR): The EUROLUPUS group will receive Cyclophosphamide (6 doses of 500 mg / fortnightly) + 3 doses of Methylprednisolone (750 mg) initial + oral glucocorticoid (GC) (prednisone) ≤ 30 mg/day with a gradual reduction of 5 mg/month (EUROLUPUS). From the 3rd month, the group will receive oral mycophenolate mofetil (MMF) (2-3 g) until 6 months with gradual reduction of GC from 5 mg/month until the minimum dose of 5 mg/month.
- Cyclones Group: Cyclophosphamide+Methylprednisolone no oral GC (Type: EXPERIMENTAL): CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)\] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) of Cervical Intraepithelial Neoplasia (CIN) Grade 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfactory colposcopy examination~* Negative endocervical canal by colposcopy~* Ectocervical CIN1 as verified by local pathologist (biopsy).~* Colposcopical visible lesion at visit 2, before photoactivation~* Written Informed Consent signed~* Age 18 or above~Exclusion Criteria:~* Previous treatment of CIN or invasive disease or suspicion of either micro-invasive or invasive disease~* Malignant cells on cytology or histology~* Atypical glandular cells (AGC) or adenocarcinoma in situ (AIS) on cytology~* Suspicion of endocervical disease on colposcopy~* Current pelvic inflammatory disease, cervicitis, or other gynecological infection as per colposcopy and clinical examination~* Known or suspected porphyria~* Known allergy to hexaminolevulinate or similar compounds (e.g. methyl aminolevulinate or aminolevulinic acid)~* Use of heart pacemaker~* Pregnancy~* Nursing~* Childbirth or miscarriage within six weeks of enrolment - Known~* Participation in other competitive clinical studies either concurrently or within the last 30 days~* Risk of poor protocol compliance~* Not willing to use adequate birth control from screening until last PDT~* Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
- 2 (Type: PLACEBO_COMPARATOR): Placebo suppository (single administration), laser illumination (50J/cm2)
- 3 (Type: NO_INTERVENTION): None
- 4 (Type: ACTIVE_COMPARATOR): HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
- 5 (Type: PLACEBO_COMPARATOR): Placebo ointment (single administration), no illumination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues